Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

仿制处方药案原告宣布达成集体诉讼和解
  • USA - español
  • USA - Traditional Chinese
  • USA - English


News provided by

Fine, Kaplan, and Black, R.P.C.

Mar 10, 2025, 15:00 ET

Share this article

Share toX

Share this article

Share toX

-仿制处方药案最终付款人原告宣布达成 2.75 亿美元集体诉讼和解,将令消费者和第三方付款人受益

费城2025年3月10日 /美通社/ --

法律声明

Fine, Kaplan, and Black, R.P.C.宣布:如果您在
2009
年5月1日至2019年12月31日期间在美国购买、支付或报销了某些仿制处方药,
则您可以从集体诉讼和解中获得赔偿。

联邦法院授权了此项声明。
此文件并非律师招揽业务的资料。

1-877-316-0171
www.GenericDrugsEndPayerSettlement.com

Para conseguir una notificación en español, llame a 1-877-316-0171 o visite el sitio web:
www.GenericDrugsEndPayerSettlement.com

美国宾夕法尼亚州东区地区法院正在审理一起集体诉讼案 (In re Generic Pharmaceuticals Antitrust Litigation(关于仿制药反垄断诉讼案), 第16-MD-2724 号),拟定的 2.75 亿美元和解金可能会影响您的合法权益。 该诉讼声称,Sandoz Inc.和Fougera Pharmaceuticals Inc.(以下简称 "Sandoz")以及其他仿制药生产商(以下简称 "非和解被告")违反了联邦和州反垄断法、消费者保护法和普通法,导致最终付款人——包括消费者和第三方付款人(以下简称 "TPP")(如保险公司或拥有自筹处方药计划的雇主等实体)在内——为某些仿制处方药(以下简称"指定仿制药")支付了超出应付金额的费用。 Sandoz否认其对最终付款人负有责任。 法院尚未裁定那一方是对的。 针对非和解被告的诉讼仍在进行中。

我是和解集体成员吗? 本诉讼的提起方是指定仿制药的最终付款人(以下简称 "EPP")。法院已初步证明了由TPP和消费者组成的EPP Sandoz和解集体。 如果您是TPP或消费者,在2009年5月1日至2019年12月31日期间的任何时候,在美国(除印第安纳州和俄亥俄州外)和美国某些地区间接购买、支付和/或报销了一种或多种指定仿制药的部分或全部购买价格,供自己或家庭成员个人使用,且未用于转售,则您有可能是和解集体的成员。 和解集体不包括某些类型的实体。 有关声明的更多详细内容,包括完整的集体描述以及其中包含的对象、指定仿制药的列表、完整的被告名单以及和解协议,请访问 www.GenericDrugsEndPayerSettlement.com。

和解协议提供了什么内容?Sandoz根据拟定的和解协议,向和解基金支付了 2.75 亿美元。 如该和解协议所述,和解基金可能会在某些情况下减少。 在扣除和解声明费用和管理费(最多75万美元)后,这笔基金将用于支付符合条件的和解集体成员;并在法院批准后,还将扣除律师费(最多为基金的三分之一,外加利息)、诉讼费(最多2,600万美元)以及和解集体代表的服务奖励(总共最多50万美元)。 和解集体法律顾问将在以下网站上公布他们的费用、开支和服务奖励申请:www.GenericDrugsEndPayerSettlement.com。 此外,Sandoz还同意与EPP合作,就EPP对非和解被告提起的诉讼提供相关信息。

我怎样才能得到付款?资金将在法院批准和解协议后发放。 相关分配计划必须经法院批准,而付款的金额和时间将以此计划为依据。 EPP拟定的分配计划公布于如下网站:www.GenericDrugsEndPayerSettlement.com。 索赔程序将在晚些时候启动。 若要获得与和解相关的最新信息,包括提供索赔表单的时间,则您应在以下网站完成注册:www.GenericDrugsEndPayerSettlement.com 或者拨打 1-877-316-0171。

如果我是和解集体成员,我有哪些选择? 如果您不采取任何行动,则将继续作为和解集体成员,有资格参与和解,并受法院关于和解协议以及向Sandoz索赔裁决的法律约束,同时您将无法再向Sandoz提出索赔。 如果您不想受到和解协议的法律约束,或者如果您想保留自己起诉Sandoz的权利,则您必须退出和解集体。 如果您选择继续留在和解集体中,但对和解协议,拟定的分配计划,律师费、开支申请或拟定的服务奖励持有部分或全部反对意见,则您可以提出反对。 有关如何申请退出或反对的详细信息,请参见 www.GenericDrugsEndPayerSettlement.com。 任何退出申请或反对意见都必须在2025年5月9日之前提交。 法院将于2025年7月23日上午11:00举行公平听证会,以决定是否批准和解协议、分配计划以及任何律师费、开支或服务奖励的申请。 如果您希望出席听证会,则您必须向法院提交一份"出庭意向通知书",您可以(但并非必须)自费聘请律师为您出庭。 法院可更改截止日期或听证日期和时间。 请查看 www.GenericDrugsEndPayerSettlement.com 以了解最新信息。

Fine, Kaplan, and Black, R.P.C.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Fine, Kaplan and Black, R.P.C. Announce Class Action Settlements on Behalf of Those Who Paid and/or Reimbursed for Certain Prescription GENERIC Drugs in the United States between May 1, 2009 and December 31, 2019

LEGAL NOTICE If You Paid or Reimbursed for Certain PRESCRIPTION GENERIC DRUGS in the United States between May 1, 2009 and December 31, 2019, You...

Fine, Kaplan and Black, R.P.C. Announce Class Action Lawsuits on Behalf of Those Who Paid and/or Reimbursed for GENERIC CLOBETASOL between September 1, 2014 and December 31, 2018 or GENERIC CLOMIPRAMINE between August 1, 2013 and December 31, 2018

LEGAL NOTICE If You Paid and/or Reimbursed for GENERIC CLOBETASOL between September 1, 2014 and December 31, 2018, or GENERIC CLOMIPRAMINE between...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Asian American

Asian American

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.